The drugmaker is holding a special shareholder meeting to vote on the appointment of a new board after the pharma giant lost ...

Novo Nordisk has found itself in an increasingly chaotic situation as of late, with shares plunging and investor confidence ...

Novo Nordisk faces a shareholder backlash on Friday as the Danish drugmaker's minority investors prepare a protest vote ...

Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing ...

Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing ...

After [losing out to Pfizer]( ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

Novo Nordisk maintains strong growth prospects, driven by obesity treatment market expansion. See why NVO stock is a strong ...

Novo Nordisk and Eli Lilly deny partnership with Mangoceuticals for weight-loss drugs, causing Mangoceuticals' shares to ...

Novo Nordisk remains a dominant business with a strong pipeline, and current multiples are low enough to justify a buy. Read my latest analysis of NVO stock.

Novo Nordisk A/S is tapping the euro bond market with a multi-tranche sale expected to raise about €3.5 billion ($4.1 billion ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, ...